Abbott Laboratories Due Diligence

Run due diligence on Abbott Laboratories: check compliance and get alerts when suppliers change.

United States · www.freestyle.abbott · 13 vendors

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and markets a broad portfolio of products. These include diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals, serving people in over 160 countries.

Resilience scores

Technology vendors

Services catalogue

2 services in catalogue across 2 categories; runs on 13 sub-vendors.

Insights

Last updated 2026-08-17 · revision 1

13 direct vendors, 172 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

10 in-scope frameworks identified; showing 3.

NIS2 (source) — No public evidence

Evidence: https://www.abbott.com/en-us/global-locations-contacts, https://www.abbott.com/privacy-policy.html, https://www.freestyle.abbott/us-en/home.html

EU MDR — Evidence found

Evidence: https://www.abbott.com/en-us/global-locations-contacts, https://www.freestyle.abbott/us-en/home.html

CPRA — Evidence found

Evidence: https://www.abbott.com/privacy-policy.html, https://www.abbott.com/en-us/privacy-policy, https://www.abbott.com/privacy-policy/consumer-health-data.html

Financials

Three-year financials

Financial Resilience Score: 9/10

Abbott Laboratories demonstrates exceptional financial resilience underpinned by a highly diversified business model spanning four major segments: Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition. This diversification substantially reduces exposure to single-market shocks, as evidenced by the company's ability to absorb the dramatic runoff of COVID-19 diagnostic testing revenue (from ~$8.4bn in 2022 to under $1bn in 2024) while still growing organic sales at high-single-digit rates. The company maintains investment-grade credit ratings (A+ / A1 area), strong free cash flow of approximately $6-7bn annually, and a fortress balance sheet with declining net debt since 2022. Abbott's status as a Dividend King (60+ years of consecutive dividend increases) signals durable long-term cash generation. Growth engines including FreeStyle Libre (growing 20%+ annually, reaching ~$6.5bn in 2024) and the Structural Heart franchise provide sustained momentum. Global footprint across 160+ countries offers geographic and currency diversification. However, risks include ongoing NEC-related infant formula litigation, the reputational aftermath of the 2022 Sturgis plant recall, FX headwinds from emerging-market exposure, and rising concentration in the Libre franchise within Medical Devices.

Key strengths: Diversification across 4 segments (Medical Devices, Diagnostics, Established Pharmaceuticals, Nutrition), Investment-grade credit ratings (A+ / A1 area), Strong free cash flow of ~$6-7bn per year, 60+ years of consecutive dividend increases (Dividend King), FreeStyle Libre blockbuster growth engine (~20%+ annual growth), Structural Heart franchise growing double digits, Global manufacturing and distribution in 160+ countries, High-single-digit organic growth excluding COVID

Risk factors: COVID-testing revenue cliff distorting historical comparisons, FX headwinds from emerging-market exposure (Latin America, India, Middle East), Ongoing Similac/NEC infant formula litigation, 2022 Sturgis, MI infant-formula plant recall reputational impact, Pricing pressure in Established Pharmaceuticals and diagnostics reimbursement, Rising concentration in FreeStyle Libre within Medical Devices

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report